A carregar...
EVALUATION OF RISK MARKERS FLUCTUATION DURING AN INITIAL THERAPY WITH ROSIGLITAZON IN PATIENTS SUFFERING FROM METABOLIC SYNDROME
The aim of this study was to examine the effects of hypoglycaemic drug-agonists of PPAR-gama recep- tors-rosiglitazone (Avandia,4 mg - Glaxo Smith Kline) on values of wide-spread risk-markers: fibrinogen, C-reactive protein and uric acid and glicolysated haemoglobin HbA1C as parameter of metabolic c...
Na minha lista:
| Publicado no: | Bosn J Basic Med Sci |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5603689/ https://ncbi.nlm.nih.gov/pubmed/20001999 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|